| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
ABSI
AbSci
|
Jun 04, 2026 | BUY |
Strong Buy
+40.1% avg upside
18 analysts
|
$12.00
67.06% Upside
|
-7.4% |
|
MIRM
Mirum Pharmaceuticals
|
May 15, 2026 | BUY |
Strong Buy
+10.1% avg upside
21 analysts
|
$154.00
50.83% Upside
|
+4.8% |
|
RGNX
RegenXBio
|
May 15, 2026 | BUY |
Strong Buy
+374.0% avg upside
22 analysts
|
$17.00
115.16% Upside
|
+0.0% |
|
ENGN
enGene Holdings
|
May 08, 2026 | HOLD |
Buy
+477.8% avg upside
13 analysts
|
$2.00
14.88% Upside
|
+16.7% |
|
NTLA
Intellia Therapeutics
|
Apr 27, 2026 | BUY |
Buy
+158.2% avg upside
37 analysts
|
$35.00
130.32% Upside
|
-7.1% |
|
CAMP
CAMP4 Therapeutics Corporation
|
Apr 02, 2026 | BUY |
Strong Buy
+131.0% avg upside
9 analysts
|
$9.00
117.46% Upside
|
-0.4% |
|
RCKT
Rocket Pharmaceuticals
|
Mar 27, 2026 | HOLD |
Buy
+418.9% avg upside
29 analysts
|
$11.00
248.19% Upside
|
-21.5% |
|
ARWR
Arrowhead Pharmaceuticals
|
Mar 26, 2026 | HOLD |
Strong Buy
-18.4% avg upside
26 analysts
|
— | +22.6% |
|
MRNA
Moderna
|
Feb 11, 2026 | SELL |
Hold
+9.4% avg upside
38 analysts
|
$12.00
80.61% Downside
|
-25.8% |
|
ALNY
Alnylam Pharma
|
Dec 15, 2025 | HOLD |
Strong Buy
+22.4% avg upside
51 analysts
|
$351.00
24.20% Upside
|
-27.8% |
|
TNYA
Tenaya Therapeutics
|
Dec 15, 2025 | BUY |
Strong Buy
+1328.2% avg upside
11 analysts
|
$2.00
181.07% Upside
|
+7.5% |
|
BBIO
BridgeBio Pharma
|
Dec 15, 2025 | BUY |
Strong Buy
+36.6% avg upside
34 analysts
|
$86.00
27.56% Upside
|
-9.6% |
|
IONS
Ionis Pharmaceuticals
|
Dec 15, 2025 | BUY |
Strong Buy
+13.0% avg upside
43 analysts
|
$100.00
34.56% Upside
|
-8.1% |
|
LXEO
Lexeo Therapeutics, Inc.
|
Oct 21, 2025 | BUY |
Strong Buy
+309.3% avg upside
11 analysts
|
$18.00
261.53% Upside
|
-47.0% |
|
FDMT
4D Molecular Therapeutics
|
Oct 15, 2025 | BUY |
Strong Buy
+272.4% avg upside
15 analysts
|
— | -8.1% |
|
CRSP
Crispr Therapeutics AG
|
Oct 15, 2025 | BUY |
Buy
+41.5% avg upside
41 analysts
|
$74.00
39.42% Upside
|
-27.6% |
|
RXRX
Recursion Pharmaceuticals
|
Oct 15, 2025 | HOLD |
Buy
+155.0% avg upside
12 analysts
|
— | -54.2% |
|
SRRK
Scholar Rock Holding
|
Sep 25, 2025 | BUY |
Strong Buy
+21.1% avg upside
23 analysts
|
$48.00
2.19% Upside
|
+36.1% |
|
BNTC
Benitec Biopharma
|
Sep 23, 2025 | BUY |
Strong Buy
+122.8% avg upside
13 analysts
|
$20.00
69.45% Upside
|
-13.1% |
|
BEAM
Beam Therapeutics
|
Sep 03, 2025 | BUY |
Strong Buy
+57.5% avg upside
25 analysts
|
— | +56.7% |
|
SDGR
Schrodinger
|
Aug 18, 2025 | BUY |
Strong Buy
+82.0% avg upside
14 analysts
|
$27.00
73.81% Upside
|
-27.9% |
|
CRBU
Caribou Biosciences
|
Aug 13, 2025 | BUY |
Strong Buy
+585.9% avg upside
12 analysts
|
$3.00
82.93% Upside
|
+9.7% |
|
NGNE
Neurogene
|
Aug 12, 2025 | BUY |
Buy
+58.4% avg upside
23 analysts
|
$70.00
127.31% Upside
|
+44.2% |
|
EDIT
Editas Medicine
|
Mar 06, 2025 | HOLD |
Buy
+434.5% avg upside
33 analysts
|
$1.00
60.81% Downside
|
+12.4% |
|
KLRS
Kalaris Therapeutics
|
Aug 09, 2024 | HOLD |
Buy
+177.8% avg upside
13 analysts
|
$1.00
77.96% Downside
|
-84.0% |
|
FR:ALSEN
Sensorion SAS
|
Jul 15, 2024 | BUY |
Strong Buy
+573.2% avg upside
5 analysts
|
— | · |
|
LENZ
LENZ Therapeutics
|
Nov 13, 2023 | HOLD |
Buy
+280.4% avg upside
17 analysts
|
$21.00
231.27% Upside
|
+374.4% |
|
SVRN
OceanPal Inc
|
Jun 08, 2023 | SELL |
Strong Buy
6 analysts
|
— | · |
|
WVE
Wave Life Sciences
|
May 23, 2023 | HOLD |
Strong Buy
+272.2% avg upside
28 analysts
|
$5.00
16.04% Downside
|
+59.8% |
|
ABEO
Abeona Therapeutics
|
Nov 14, 2022 | HOLD |
Strong Buy
+200.8% avg upside
17 analysts
|
$6.00
6.15% Upside
|
+2.4% |
|
TECX
Tectonic Therapeutic
|
Oct 19, 2021 | HOLD |
Strong Buy
+88.0% avg upside
24 analysts
|
— | -88.5% |
|
SRPT
Sarepta Therapeutics
|
Nov 06, 2020 | BUY |
Buy
+251.8% avg upside
49 analysts
|
$197.00
1061.57% Upside
|
-29.2% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.